Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]
March 31, 2022
Inside the Race to Make Psychedelics ‘Mainstream Medicines’ [Endpoints News]
March 29, 2022
Five Companies Developing Second Generation Psychedelics For Mental Health [Benzinga]
March 24, 2022
Groundbreaking Trial to Explore Psychedelic Therapy for Cancer Distress [Psychedelic Health]
February 21, 2022
Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary [via Benzinga]
February 17, 2022
UCalgary to Collaborate on Clinical Trial Assessing Psychedelic Treatments and Cancer Related Distress [The Edmonton Journal]
February 17, 2022
Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis [IPO Edge]
February 8, 2022
Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis [Benzinga]
February 8, 2022
How AI Could Unlock the Medical Potential of Psychedelics
January 28, 2022
Here’s What Happens When Psychedelics Meets AI [Green Market Report]
January 24, 2022
‹
1
…
5
6
7
8
9
…
12
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
